Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope by unknown
Cytotoxic  T  Lymphocyte  Response  to  a Wild Type 
Hepatitis  B  Virus Epitope  in Patients  Chronically 
Infected  by Variant Viruses  Carrying  Substitutions 
within  the  Epitope 
By Antonio Bertoletti,* Antonio Costanzo,~ Francis V. Chisari,g 
Massimo Levrero,~ Marco Artini,~ Alessandro Sette,  II 
Amalia Penna,* Tiziana Giuberti,* Franco Fiaccadori,* 
and Carlo Ferrari* 
From the  *Cattedra Malattie Infettive, Universith di Parma, 43100, Parma, Italy; ~Fondazione 
A.  Cesalpino and I  Clinica Medica, Universith "La Sapienza," 00161 Roma,  Italy; 
SDepartment of Molecular and Experimental  Medicine, The Scripps Research Institute, La Jolla, 
California 92037; and JtCytet Corporation, LaJolla,  California 92037 
Summary 
Mutations that abrogate recognition of a viral epitope by class I-restricted cytotoxic T lymphocyte 
(CTL) can lead to viral escape if the CTL response against that epitope is crucial for viral clearance. 
The likelihood of this type of event is low when the CTL response is simultaneously directed 
against multiple viral epitopes, as has been recently reported for patients with acute self-limited 
hepatitis B virus (HBV) infection. The CTL response to HBV is usually quite weak, however, 
during chronic HBV infection, and it is generally acknowledged that this is a major determinant 
of viral persistence in this disease. If such individuals were to produce a mono- or oligospecific 
CTL response, however, negative selection of the corresponding mutant viruses might occur. 
We have recently studied two HLAoA2-positive patients with chronic hepatitis B who, atypically, 
developed a strong HLA-A2-restricted CTL response against an epitope (FLPSDFFPSV) that 
contains an HLA-A2-binding motif located between residues 18-27 of the viral nucleocapsid 
protein, hepatitis B core antigen (HBcAg). These patients failed,  however, to respond to any 
of other HLA-A2-restricted HBV-derived peptides that are generally immunogenic in acutely 
infected patients who successfully clear the virus. Interestingly, DNA sequence analysis of HBV 
isolates  from these two patients demonstrated alternative residues at position 27 (V --~ A and 
V --~ I) and position 21 (S --~ N, S --~ A, and S -'~ V) that reduced the HLA and T cell receptor- 
binding capacities of the variant  sequences,  respectively. Synthetic peptides containing these 
alternative sequences were poorly immunogenic compared to the prototype HBc18-27 sequence, 
and they could not be recognized by CTL clones specific for the prototype peptide. While we 
do not know if the two patients were originally infected by these variant viruses or if the variants 
emerged subsequent to infection because of immune selection, the results are most consistent 
with the latter hypothesis. If this is correct, the data suggest that negative selection of mutant 
viral genomes might contribute to viral persistence in a subset of patients with chronic HBV 
infection who express  a narrow repertoire of anti-HBV CTL responses. 
H 
LA class I-restricted, anti-viral cytotoxic T cells recog- 
nize short viral peptides that are generated by the in- 
tracellular processing of endogenously synthesized viral an- 
tigen within infected cells (1, 2),  and are expressed at the 
cell surface in the binding groove of selected HLA class I 
molecules (3-7). Peptide binding to HLA class I molecules 
is dependent on interactions between conserved MHC residues 
and main chain atoms at both peptide termini (8-13), as well 
as selective interactions between allele-specific MHC pockets, 
formed by polymorphic MHC residues, and side chains of 
peptide anchor residues, pointing towards the floor of the 
HLA groove (14-17).  Residues of the MHC bound peptide 
particularly accessible to TCR recognition are located in the 
central portion of the antigenic sequence that can face out- 
wards from within the MHC binding groove (18). 
Single amino acid substitutions of MHC anchor residues 
or TCR contact sites have been shown to abrogate CTL re- 
sponses in vitro by inhibiting either HLA binding or TCR 
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is conceivable that mutations that destroy CTL epitopes may 
permit viral escape and the establishment of viral persistence 
by the variant virus in vivo. Indeed, this has been shown to 
occur in transgenic mice that express a lymphocytic chorio- 
meningitis virus-specific  T cell receptor and produce a mono- 
clonal cytotoxic response that is focused on a single CTL epi- 
tope (20). 
In contrast to these TCR transgenic mice, the CTL re- 
sponse  during human viral infections is usually polyclonal 
and multispecific which virtually precludes the emergence 
of escape mutants (21-26).  Nonetheless, HIV genomes con- 
taining mutations within an HLA-B8-restricted HIV gag 
CTL  epitope  have  been  shown  to  emerge  in  an  HIV- 
seropositive donor (27), and a dominant EBV genotype that 
contains an  inactivating substitution within an immuno- 
dominant HLA-A11-restricted CTL epitope has been reported 
in a high HLA-All frequency human population (28). Thus, 
it is possible that functionally monospecific CTL responses 
to certain viruses that create the conditions required for the 
negative selection of CTL escape mutants may occur during 
infection by pathogenic human viruses. 
During acute hepatitis B virus (HBV) 1 infection most pa- 
tients develop a strong, polyclonal CTL response against mul- 
tiple epitopes in the viral envelope,  nucleocapsid, and polyo 
merase proteins, that is vigorous enough to be detected in 
the peripheral blood (26,  29-31; Rehermann, B., J. Person, 
A. Redeker, P. Fowler, M. Brown, B. Moss,  A. Sette,  and 
F, V.  Chisari, manuscript in preparation).  In contrast, the 
peripheral CTL response to HBV is usually not detectable 
in chronically infected patients (26, 30). In the present study 
we describe  two patients with chronic HBV infection who 
displayed a vigorous HLA-A2-restricted CTL response against 
a prototype nucleocapsid epitope located between residues 
18-27 of HBcAg (32).  Interestingly, these patients were in- 
fected by viruses that code for poorly immunogenic variants 
of the prototype epitope that are also inefficiently  recognized 
by CTL with prototype HBc18-27 epitope specificity. The 
implications of these findings with respect  to mechanisms 
of virus persistence  and disease pathogenesis are discussed. 
Materials and Methods 
Patients.  Four patients with acute hepatitis type B, nine patients 
with chronic HBV infection, and four healthy subjects were studied. 
The diagnosis of acute hepatitis B was based on the finding of 
elevated values of serum alanine aminotransferase (ALT) activity 
(at least 10 times the upper limit of the normal), associated with 
the detection of IgM antibodies against hepatitis B core antigen 
in the serum, and the recent onset of  jaundice and other typical 
symptoms of  acute hepatitis. All acute patients recovered  completely 
from the illness with normalization of transaminase and clearance 
of hepatitis B surface antigen from the serum. The diagnosis of 
chronic hepatitis type B was based on biochemical and histological 
findings. No patient was receiving corticosteroid or antiviral drugs. 
All were antibody negative to HIV, hepatitis C, and delta viruses. 
1 Abbreviations used in this paper: ALT, alanine aminotransferase;  EBV-B, 
EBV-transformed B; HBV, hepatitis B virus; r, recombinant. 
DNA  Preparation.  For the amplification of circulating HBV- 
DNA genomes, sera (100 #1) were heated at 100~  for 30 rain, 
centrifuged at 12,000 g for 30 min, and 5/A of the supernatants 
were directly used for PCR. Total cell DNA was extracted from 
fresh PBMC and liver infiltrating T cells of HBV-infected  patients 
by the proteinase K method. Pellets  of 1-5  x  106 cells were lysed 
in 500/xl of 10 mM Tris, pH 8,  10 mM EDTA, 10 mM NaC1, 
and 0.5% SDS. 2 #1 of 20 mg/ml proteinase K were immediately 
added and  the  lysate was  incubated at  56~  for  3  h.  After 
phenol/chloroform  extraction  and ethanol  precipitation, DNA 
pellets were redissolved  in sterile distilled water, and stored at 4~ 
1 #g of DNA was used in each amplification. Purification of  DNA 
from formaldehyde-fixed  and paraffin-embedded  liver tissue  was per- 
formed according to Wright et al. (33) with minor modifications. 
Briefly, 5-#m-thick liver biopsy sections were extracted twice with 
mixed xylenes and washed twice in ethanol. Deparaffinated liver 
tissue was then resuspended in 100 #1 of lysis buffer (see above) 
containing 200 #g/#l of proteinase K and incubated at 37~  over- 
night. DNA was then extracted as already described and one third 
of each preparation was used for amplification. 
PCR Protocol.  DNA was amplified  in 100 #1 of  a reaction  buffer 
containing 10 mM Tris-HC1, pH 8.3, 50 mM KC1, 1.5 mM MgC1, 
100/~g/ml of gelatin, and 20 pM of each primer. Samples were 
subjected to 40 cycles of amplification in a DNA thermal cycler 
(Perkin Elmer Corp., Norwalk, CT). The cycling  conditions were 
1 min at 94~  1 min at 54~  and 1 min at 72~  The primers 
core 1: 5'-ACTAGGAGGCTGTAGGCATAAATTGGTCT-Y  (1774- 
1802), core 2: 5'-GCAGTATGGTGAGGTGAACA-Y  (2063-2044), 
core 3: 5'-TCACCTCACCATACTGCACT-Y  (2046-2066), core 4: 
5'-TTCCCGAGATTGAGATCTTCTGCGACGCGGCGATTG- 
AGA-Y (2442-2404) were derived from the precore-core region 
of HBV genome genotype D (34). 
Cloning and Sequencing  of PCR Products.  PCR products were 
treated with the Klenow fragment of the DNA polyrnerase I (Phar- 
macia, Uppsala, Sweden) to remove  single base 3' overhangs, phos- 
phorylated by T4 polynucleotide kinase (Pharmacia), phenol/chlo- 
roform extracted, purified on a Sephacryl  S 200 micro spin column, 
and cloned into a pUC18 vector at the SmaI site. Several clones 
for each ligation were sequenced  using a standard dideoxy method 
with a fluorescent M13 primer according to manufacturer instruc- 
tions (Autoread Sequencing  kit; Pharmacia). For direct sequencing 
of PCR products the amplification  reactions were performed using 
a biotinylated core 1 primer. Amplification  products were separated 
in a 2% agarose gel, the 289-bp length fragments extracted with 
a silicagel  suspension (Quiaex gel extraction; Diagen, Dusseldorf, 
Germany) and the biotinylated strand immobilized on streptavidin- 
coated magnetic  beads (Dynabeads  M-280 Streptavidin;  Dynal, Oslo, 
Norway). The single-strand template was annealed at 68~  for 5 
rain with 5 pM of the fluorescein-labeled  sequencing primer (5'- 
GCAGTATGGTGAGGTGAACA-Y)  in 10 mM Tris-HC1 (pH 7.5), 
100 mM NaC1, 10 mM MgC12, and bovine serum albumine (0.1 
mg/ml). The reactions were cooled at 55~  and incubated for 10 
min. After a further incubation for 3 min at 37~  3 U of T7 
DNA polymerase (Pharmacia), 6 mM diothiothreitol, and 45 mM 
NaC1 were added. Reactions from both plasmid DNA and single- 
strand immobilized templates  were then divided  into four portions, 
mixed with one of the four dideoxy nucleotides, and incubated 
for 3 min at 37~  An equal volume of deionized formamide con- 
taining Blue dextran (5 mg/ml) was added and the samples were 
loaded onto a 0.5-ram-thick 6% polyacrylamide-7 M urea gel and 
run on A.L.F. DNA Sequencer (Pharmacia). 
Synthetic Peptides and A ntigens.  The complete panel of  peptides 
corresponding to the HBV nucleocapsid  region 18-27 containing 
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two patients with chronic hepatitis B were purchased from Chiron 
Mimotopes (Clayton, Victoria, Australia).  The panel of peptides 
(9- or 10-amino acids long) corresponding to the HBV sequences 
containing the A2-binding motif were kindly provided by Cytel 
(San Diego, CA). They were routinely >90% pure after reverse- 
phase high pressure liquid chromatography￿9 
Recombinant (r)HBcAg was obtained from bacterial extracts of 
Escherichia coli as previously described (35). Tetanus toxoid protein 
was purchased from Connaught  Laboratories (Swiftwater, PA). 
Generation ofHBV-s~cific  CTL.  Polyclonal CTL lines were pro- 
duced as previously described (29,  30). Briefly, PBMC were iso- 
lated from fresh heparinized blood by Ficoll-Hypaque density gra- 
dient centrifugation and resuspended at 4  x  106 cells/ml in RPMI 
1640 containing 10% AB serum￿9 Cells were stimulated with the 
different peptides in the presence of 1/zg/ml of rHBcAg (Biogen, 
Geneva, Switzerland) in a 96-well plate (Falcon Labware, Oxnard, 
CA). In selected experiments, tetanus toxoid (1/~g/ml) instead of 
rHBc was used as an alternative source of helper effect￿9 rlL-2 (20 
U/ml; Hoffmann La Roche, Basel, Switzerland) was added on day 
4 of culture and the cytotoxic assays were performed on day 7. 
Production of HBc18-27-specific CTL Clones.  Oligoclonal CTL 
lines  were generated from HBc18-27-specific polyclonal lines by 
limiting dilution at 1, 10, and 100 cells/well￿9 Cells were plated in 
the  presence  of irradiated  (7,000  R)  HLA  A2  matched  EBV- 
transformed B (EBV-B) cell lines (1  x  10S/ml),  allogeneic irradi- 
ated (5,000 R) PBMC (1  x  106/ml),  the HBc18-27 peptide (100 
nM) and PHA (1:200;  GIBCO BILL,  Gaithersburg,  MD).  Res- 
timulation was carried out every 10 d. HBc18-27-specific  CTL lines 
were then recloned at 0.5 cells/well with  the same protocol. 
Cytotoxicity Assays.  CTL lines and clones were tested for their 
cytolytic activity against autologous or allogeneic HLA-A2-posi- 
tive EBV-B cells as targets, labeled with 100 #Ci SlCr (NaStCrO4; 
Amersham International,  Buckinghamshire, England) for 1 h at 
37~  Target cells were then washed twice, diluted in RPMI con- 
taining 10% FCS, and incubated for I h with different concentra- 
tions of the appropriate peptide, before co-culture with effector 
CTL at different E/T ratios in 96-well round bottomed plates. The 
amount of SlCr released  in the culture supernatants was quanti- 
tared after 4 h of incubation and percent cytotoxicity was deter- 
mined using the following formula: (E  -  M/D  -  M)  x  100, 
where E  is  the  experimental S*Cr release  (cpm);  M  is the  S*Cr 
released in the presence of culture medium (which ranged between 
15 and 25% of total releasable counts); D is the total SlCr released 
in the presence of 10%  Triton X. 
HLA-A2.I Binding Assay.  The quantitative assay used for HLA- 
A2.1-binding peptides based on the inhibition of binding of a ra- 
diolabeled standard peptide to detergent-solubilized HLA mole- 
cules  is described elsewhere (36). 
Results 
An  E.~cient  CTL  Response against the HLA-A2-restricted 
Epitope  HBc  18-27  Is Expressed  by  Some  Chronic  HBV  Pa- 
tients.  In  the  present  study  we  analyzed  the  HBc  18- 
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Figure  1.  Long-term  follow- 
up of the CTL response against 
the  HLA-A2-restricted  epitope 
HBc18-27. A illustrates the CTL 
response displayed by one of the 
two chronic patients infected by 
the  HBc  21/27  variant  virus, 
whereas B and C  illustrate the 
results obtained in two represen- 
tative HLA-A2-positive chronic 
patients  infected by  prototype 
HBc18-27 virus.  Chronic  non- 
responder patients did not express 
signficant levels of CTL activity 
even when  peptide  stimulation 
was performed in the presence of 
tetanus  toxoid as an  additional 
source of helper activity, despite 
the fact that this strategy proved 
effective in potentiating the pep- 
tide stimulatory capacity in sev- 
eral  experiments  performed  in 
HLA-A2-positive  acute  and 
chronic peptide-responder  patients 
(data not shown). Concentrations 
of serum HBV-DNA detected at 
different time points by a commer- 
cially available hybridization kit 
(HBV  Chronic,  Eurospital, 
Trieste, Italy) are also illustrated. 
Arrows, black circle, asterisk, and 
empty circle  indicate the dates when 
virus sequencing was performed 
from DNA extracted from serum, 
liver  tissue, PBMC  and  intra- 
hepatic T cells, respectively. 
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with chronic HBV infection, two of whom repeatedly dis- 
played a significant  CTL response against  HBc 18-27 after 
1 wk of peptide stimulation,  despite their inability to clear 
HBV infection.  In one of these two responders  (patient  1) 
the CTL response was repeatedly examined over a time period 
of more than 3 yr, showing wide fluctuations of the cyto- 
toxic activity from negative to  strongly positive responses 
(Fig.  1 A).  This finding contrasts  with the consistent lack 
of CTL responsiveness in the majority of HLA-A2-positive 
patients with chronic hepatitis (reported in references 26, 30; 
and illustrated in Fig.  1, B  and C). 
Amino Acid Substitutions within the CTL Epitope HBc 18-27 
Are Present in HLA-A2-positive Chronic HBV Patients.  To 
investigate the basis for viral persistence despite CTL respon- 
siveness  in these two patients,  the entire precore and core 
genes of 49 serum-derived viral genomes were amplified and 
sequenced.  100%  (49/49) of the genomes sequenced from 
these  two  patients  displayed  amino  acid  substitutions  at 
HBcAg positions 21 and 27 (Table I) relative to the published 
HBV-DNA sequences of the prototype genotype D (which, 
together with genotype A, is prevalent in Western Europe 
and North America;  34, 37) and to HBV DNA sequences 
obtained from 10 HLA-A2-negative patients with chronic 
hepatitis  B  derived  from  our  geographical  area  (data  not 
shown).  In patient  1,  serine 21 and valine 27 were consis- 
tently substituted by asparagine and alanine,  respectively, at 
all time points studied over a 4-yr period (1990,  1992,  and 
1993;  Fig.  1 A).  Patient  2 was studied only once, but his 
virus population  was dominated  (17/18  sequenced clones; 
94%) by a variant that displayed an alanine for serine substi- 
tution  at position 21,  and isoleucine for valine at position 
27, while the remaining  clone contained a serine to valine 
substitution at position 21, and a valine to isoleucine at posi- 
tion 27 (Table 1). Similarly, all viral genomes isolated from 
liver tissue, PBMC, and an intrahepatic  lymphocyte T  cell 
line in patient 1 displayed asparagine 21 and alanine 27 sub- 
stitutions  (not  shown). 
In contrast,  the HBcAg 18-27  sequence in  100%  of the 
viral genomes derived from the serum of the other five HLA- 
A2-positive chronically infected, CTL-nortresponsive, patients 
was identical to the prototype sequence with the exception 
of a single conservative substitution of Phe 24 with Tyr in 
one patient (Table 1). Similarly, the prototype epitope sequence 
was detected in 2/2 HLA-A2-positive, CTL-responsive pa- 
tients with  acute hepatitis. 
In the precore region, base substitutions introducing a stop 
codon at amino acid positions 28 (G to A at nucleotide 1896) 
and 29 (G to A at nucleotide 1899) were detected in all viral 
genomes sequenced from the two chronic patients displaying 
the variant  HBc18-27 epitope (patient  1 and 2 in Table  1) 
and one acute patient (patient 8 in Table 1). In contrast, the 
same substitutions were present at both of these positions 
in 17 and 8% of the viral clones sequenced from chronic pa- 
tients 3 and 4, respectively, and a single substitution at posi- 
tion 1896 was found in 12% of the DNA clones derived from 
chronic patient 5. The remaining patients showed prototype 
precore sequences. 
Table  1.  Sequencing Analysis of the HBc18-27 Region in HLA-A2-positive  Patients with Chronic and Acute 
Self-limited HBV Infection 
HLA-A2 anchor  residues 
Wild type  18  19  20  21  22  23  24  25  26  27 
Sequence  PHE  LEU  PRO  SER  ASP  PHE  PHE  PRO  SER  VAL 
Chronic 
patients 
Acute 
patients 
m 
m 
m 
m 
m 
Percent viral 
genomes 
-  ASN  .....  ALA  100 
-  ALA  .....  ISO  94 
--  VAL  .....  ISO  6 
........  100 
........  100 
........  100 
....  TYR  --  --  --  100 
........  100 
8  ..........  100 
9  ..........  100 
The percentage of DNA clones with wild type or variant sequence is illustrated. The amino acids acting as anchor residues  for binding to HLA-A2 
are indicated by arrows. 
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Binding Affnity of  Peptide HBc 18-27  for HLA-A2.1.  Peptides 
containing the amino acid sequence deduced from the nat- 
ural  variants  were  synthesized to  study  the  influence of 
the natural substitutions  on the binding of the prototype 
HBc18-27  peptide  to  HLA-A2.1  molecules. The binding 
affinity of the variant peptides was compared to that of the 
prototype 18-27 peptide by testing their capacity to compete 
with a reference-radiolabeled peptide for the binding to purified 
HLA-A2.1 molecules, as recently described (36). 
As predicted from the crystallographic model of peptide 
binding to HLA-A2.1 molecules (18),  the binding affinity 
of the peptides carrying amino acid substitutions at position 
21 was the same as the prototype peptide (Table 2). In con- 
trast, the binding affinity was decreased 10-20-fold when va- 
line 27 (an anchor residue) was substituted by either isoleu- 
cine or alanine (Table 2).  Although the binding afffnity of 
the substituted peptides remained within the range of affinity 
of known HLA-A2-restricted epitopes, it would not be sur- 
prising if the decreased affinity might cause the corresponding 
natural variant viruses to be less immunogenic than the pro- 
totype. 
The Natural Substitutions of HBc Residues 21 and 27 Can 
Abrogate Peptide Recognition by CTL.  A large panel ofcyto- 
toxic T cell clones and lines specific for the prototype HBcAg 
18-27  sequence was  generated from  two  different HLA- 
A2-positive patients with acute hepatitis B in order to study 
the influence of the natural substitutions in the epitope on 
its ability to be recognized by prototype-specific CTL. The 
prototype-specific CTL clones were HLA-A2 restricted and 
were able to recognize endogenous core antigen synthesized 
within the target cells following infection with recombinant 
vaccinia virus (29)  as efficiently as the synthetic prototype 
HBc 18-27 peptide (data not shown). Individual CTL clones 
showed different patterns of reactivity against the variant pep- 
tides. More than half (15/29) of the clones tested (e.g., clones 
M4 and G29 in Fig. 2) were incapable of recognizing pep- 
tides containing substitutions at residues 21 and 27 even at 
very high peptide concentrations. The rest of the clones were 
less profoundly influenced by the substitutions,  requiring 
higher concentrations of the variant versus the prototype pep- 
tide to yield equivalent cytolytic activity (e.g., clones G13, 
G33,  and G3.13 clones in Fig. 2).  Similar results were ob- 
tained with peptides corresponding to the natural variants 
from chronic patient 1 (Ash 21 and Ala 27; Fig.  2, top) and 
chronic patient 2 (Ala or Val 21 and Ile 27; Fig. 2, bottom). 
The foregoing results were confirmed with polyclonal CTL 
lines derived from HLA-A2-positive acute patients by PBMC 
stimulation with prototype HBc18-27 peptide, indicating that 
the findings at the clonal level were representative of the poly- 
clonal repertoire within acutely infected patients (Fig.  3, B 
and C). Furthermore, an oligoclonal line derived from chronic 
CTL responder patient 1 (infected by the variant HBc Ash 
21-Ala 27 virus) by stimulation with the prototype peptide 
was unable to recognize peptides containing either the double 
21/27  substitution or the substitution  of residue 21 alone 
(Fig.  3 A), suggesting that the in vitro observations might 
be pertinent to in vivo events in the chronically infected pa- 
tient himself. 
Serine at position 21 seemed to be involved in peptide rec- 
ognition by the TCR because its  substitution  with either 
asparagine or alanine or valine abolished peptide recognition 
(Fig.  2) without affecting HLA binding affinity (Table 2). 
This was confirmed by competition experiments in which 
variant Asn 21 or Ala 21 peptides effectively blocked recog- 
nition of the prototype peptide by T  cell clones (data not 
shown). In contrast, conservative substitution of the valine 
anchor residue at position 27 with either alanine or isoleu- 
cine, which decreases HLA binding 10-20-fold, (Table 2) im- 
posed a requirement for high peptide concentration for cyto- 
Table  2.  Peptide  Binding to Purified HLA-A2.1  Molecules 
AA sequence  Binding to HLA-A2.1 
Fold reduction 
compared to WT  IC50%  nM 
FLPSDFFPSV  (WT)  -  1.2  +- 0.3 
FLPNDFFPSA  (Asn21-Ala27)  12.5  15  _+ 4.0 
FLPNDFFPSV  (Asn21)  -  1.4  _  0.35 
FLPSDFFPSA  (Ala27)  19  23  _  0.5 
FLPADFFPSI  (Ala21-Ile27)  19.2  11  _+ 2.4 
FLPADFFPSV  (Ala21)  -  1.3  _  0.15 
FLPVDFFPSI  (Va121-Ile27)  19  23  +  6.6 
FLPVDFFPSV  (Va121)  -  1.9  __  0.35 
FLPSDFFPSI  (Ile27)  9.1  10.9  _+ 3.0 
Binding is expressed  as IC50% (50% inhibitory  concentration)  that represents  the dose of test competitor  peptide yielding  50% inhibition of reference 
radiolabeled peptide binding. 
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Figure 2.  Cytotoxic response of HBc18-27-specific CTL clones against different concentrations of prototype and variant HBc18-27 peptides. CTL 
clones raised against prototype  HBc18-27 were derived from patients with acute self-limited HBV infection. The upper panel shows the CTL response 
against synthetic peptides corresponding  to the variant 21/27 sequence with Asn at position 21 and Ala at position 27 found in chronic patient  1; 
the lower panel illustrates the results obtained with peptides containing the natural substitutions (Ala or Val 21 and Ile 27) found in chronic patient 2. 
lytic activity to be expressed (data not shown). These results 
strongly suggest that residue 21 is a critical TCR contact 
site for a large proportion of CTL that recognize the proto- 
type HBc 18-27 sequence, and that substitution of this res- 
idue can strongly influence the CTL response by abrogating 
peptide recognition. 
Induction of the CTL Response by Prototype and Variant  HBc18- 
27 Peptides in HLA-A2-positive Chronic and Acute Patients.  The 
effect of the naturally occurring substitutions on the induc- 
tion phase of the cytotoxic response was investigated next, 
by comparing the capacity of variant and prototype HBc 18- 
27 peptides to stimulate the CTL response of peripheral blood 
T cells from HLA-A2 positive, chronic, and acute hepatitis 
B patients.  The length of peptide  stimulation was limited 
to 7 d to minimize the risk of inducing primary in vitro CTL 
responses. As expected, following stimulation of PBMC from 
chronic patients infected by the variant virus with the proto- 
type peptide,  the 21/27  analogue peptide was either recog- 
nized less efficiently than the prototype peptide  (Fig. 4 A, 
experiment 1) or not recognized at all (Fig. 4 A, experiments 
2 and 3). On the other hand, PBMC stimulation with the 
variant peptide was ineffective in CTL induction even  at pep- 
tide concentrations up to  100 #M (Fig. 4 B). 
Not surprisingly, CTL induction with 21/27 variant pep- 
tides in acute HLA-A2-positive patients infected by viruses 
that express the prototype peptide was much less effective 
than induction with prototype HBc 18-27 (Fig. 5 A). In- 
deed, frequently the variant peptides were totally unable to 
expand CTL specific either for themselves or for the proto- 
type sequence, as illustrated by the representative experiment 
in Fig. 5 B. 
It is noteworthy that the single substitution of valine 27 
with either alanine or isoleucine completely abolished CTL 
induction in both acute and chronic patients even at peptide 
concentrations as high as 1 #M that, in contrast, can efficiently 
sensitize target cells for recognition by 18-27 specific CTL 
(Fig. 2). Similarly, the substitution of residue 21 with either 
asparagine or alanine had a drastic negative effect on the in- 
duction phase of the CTL response (data not shown). 
Finally, no cytotoxicity was observed in HLA-A2-posi- 
rive chronic HBV patients  infected by prototype virus and 
in healthy HLA-A2-positive control individuals following 
PBMC stimulation with prototype and variant peptides (data 
not shown).  Taken together, these results indicate that the 
variant HBc 21/27 peptide is less immunogenic than its pro- 
totype counterpart, in patients  chronically infected by the 
HBV 21/27 variant and suggest that their in vivo CTL re- 
sponses to the prototype HBc 18-27 sequence are probably 
ineffective against the prevalent infecting variant virus. 
Analysis of the CTL Repertoire in Patients Chronically Infected 
by the HBc.Ag 21/27 Variant and Patients Acutely Infected by the 
Prototype Virus.  The CTL repertoire in the HLA-A2-posi- 
tive chronic patient 1 infected by the variant virus was studied 
using a panel of 77 different peptides, 9- or 10-amino acids 
in length, selected  by scanning the entire amino acid sequence 
of HBV for the presence of the HLA-A2 binding motif de- 
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tion of oligoclonal and polyclonal CTL lines is described in Materials and 
Methods.  Lysis of target  cells pulsed with 1 pM peptides is illustrated. 
scribed by Rammensee et al.  (15). Each peptide contained 
a leucine or isoleucine at position 2 and valine or leucine or 
isoleucine at the carboxyterminal position. Remarkably, the 
CTL response in patient 1 chronically infected by the HBc 
21/27 variant was selectively focused on the prototype HBc 
18-27 sequence (Fig. 6). This is in striking contrast with the 
muhispecificity of the CTL response expressed by patients 
with acute self-limited hepatitis B,  that is simultaneously 
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Figure 4.  CTL induction  with prototype HBc18-27 and variant Asn21- 
Ala27 peptides in chronic patient 1. PBMC were stimulated either with 
prototype  or with variant Asn21-Ala27 peptides (1/.tM) for 7 d and then 
tested against HLA-A2-positive target cells pulsed either with prototype 
or with variant peptides (1 pM) or with medium alone. No CTL activity 
was induced even at concentrations  of 10 and 100/~M of variant peptide 
(data not shown). 
directed against multiple epitopes scattered  throughout the 
different HBV antigens (26,  30;  and data not shown). 
Discussion 
Cytotoxic T cells play an essential role in the control of 
viral infections (38-43). For example, patients with acute HBV 
infection who successfully clear the virus develop a polyclonal, 
multispecific CTL response against several epitopes in the viral 
envelope, nucleocapsid, and polymerase proteins that is vig- 
orous enough to be detectable in the peripheral blood lym- 
phocyte compartment (26, 29-31; and Rehermann, B. et al., 
manuscript in preparation). In contrast, the peripheral CTL 
response to HBV is usually undetectable or extremely weak 
in patients who fail to clear the virus and develop chronic 
hepatitis (26,  30). 
The two patients with chronic active hepatitis B described 
in the present report represent an exception to this general 
rule. Despite their persistent infection, for unknown reasons 
they displayed a strong CTL response against a conserved, 
HLA-A2-restricted epitope (FLPSDFFPSV)  that is located 
between residues  18-27 of the prototype HBcAg sequence 
that carries  the HLA-A2 binding motif of Rammensee et 
al. (15). The CTL response to this epitope was comparable 
in intensity and capacity to recognize endogenously synthe- 
sized antigen as the response produced by patients who ulti- 
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Figure 6.  CTL response against HBV peptides containing the HLA- 
A2 binding motif. PBMC from chronic patient 1 infected by the Asn21- 
Ala27 variant virus were stimulated for 7 d with 1 #M of each peptide 
and then tested against HLA-A2-positive target cells pulsed either with 
the corresponding stimulatory peptide or with medium alone. Identical 
results were obtained  in two further experiments in chronic patient 1 (re- 
sponse focused  on HBc18-27). In two HLA-A2-positive  patients  with acute 
self-limited hepatitis B infected by prototype HBc18-27 virus and studied 
with the same panel of synthetic peptides, significant levels of cytotoxic 
activity were expressed simultaneously  against several  peptides (one within 
polymerase, three in the nucleocapsid, and two in the envelope region in 
one patient; one within the x, one in the polymerase, and two in the 
envelope region in the second patient). 
matdy clear the virus during an episode of acute viral hepa- 
titis,  yet  the virus persisted in  these patients. 
To understand the basis for viral persistence in the pres- 
ence of this CTL response, we examined the ability of the 
patients to respond to 79 additional HBV-derived  peptides 
containing the HLA-A2 binding motif, and we determined 
the DNA sequence of the viruses that infected these patients. 
Unlike patients with acute hepatitis, the two chronically in- 
fected CTL responders failed to respond to any of the other 
known HLA-A2-restricted  CTL epitopes in HBV. Further- 
more,  they were infected by viruses containing amino acid 
substitutions of HLA-binding  (position 27) and TCR. con- 
tact (position 21) residues in the prototype HBc  18-27 epi- 
tope that severely impaired its immunogenicity and its ability 
to be recognized  by prototype-specific  CTL. 
Three important questions emerged from these observa- 
tions. First, why did these two patients respond at all? Second, 
why was their response limited to a single epitope?  Third, 
why did the virus persist in the face of this response? While 
we can only speculate in the most general terms about the 
influence of host genetics, viral genotype and epitope domi- 
nance with respect  to the first two questions,  the available 
data permits us to at least discuss two reasonable alternatives 
for the persistence of a variant virus in the face of a limited 
CTL response to an epitope  that it  cannot  produce. 
Because the identity of the primary infecting viruses cannot 
be determined by direct analysis,  either these two patients 
were originally infected by the variant genomes, or they were 
infected by a prototype virus that subsequently mutated and 
was negatively selected by the prototype HBc 18-27-specific 
CTL  response that they produced. 
For the first hypothesis to be correct the patients would 
have to be primed in vivo by the variant epitope resulting 
in a CTL response that is neither strong enough to mediate 
clearance  of the variant viruses not to be boosted by the ho- 
mologous variant peptides  in vitro,  but is sufficient to be 
boosted in vitro by the prototype epitope (presumably be- 
cause it displays higher binding affinity than the variant for 
the HLA-A2  molecule  and the CTL T  cell receptor).  Ac- 
cording to this hypothesis, preferential recognition of the pro- 
totype HBc  18-27 epitope might reflect  priming in vivo by 
a high concentration  of the "low  affinity" variant epitope 
and cross-reactivity with lower concentrations of the "high 
affinity" prototype sequence. Under these circumstances the 
CTL could be detectable  in vitro by their capacity  to kill 
target cells pulsed with low doses of the prototype peptide 
and high doses  of the variant peptides. 
The hypothesis is unattractive for several reasons. First, our 
inability to derive a variant-specific CTL response in either 
of these two patients,  even at very high concentrations  of 
variant peptide (100/~M),  precludes definitive testing of the 
idea.  Second, since serine 21 in the prototype sequence was 
shown to be a crucial TCR contact site for polyclonal and 
oligoclonal T  cell lines derived from chronic patient  1 it is 
most likely that circulating T cell clones that recognize this 
residue were primed in vivo by prototype virus. Third, our 
own data and the HBV sequence database  indicate that the 
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tures of the viruses infecting the two chronic patients in this 
study, suggesting that the variants probably originated during 
the course of the infection in these specific individuals. The 
finding that substitutions of HBcAg residues 21 and 27 are 
different in the two chronic patients confirms that they were 
not infected by a single virus type that might be widespread 
throughout  the  geographical  area  from  which  they were 
drawn, and suggests that these variants may be relevant only 
to the individuals  within  which they evolved. 
Several observations make the second hypothesis more at- 
tractive: first, the CTL repertoire is uncommonly narrow in 
the patients infected by the variant virus and apparently fo- 
cused on the HBV region where mutations  arose;  second, 
natural  substitutions can abrogate the cytotoxic activity of 
CTL specific for the prototype epitope; third, the variant pep- 
tide is poorly immunogenic compared to the prototype. How- 
ever, this hypothesis remains indirect because we did not ob- 
serve a conversion from prototype to variant viral genotype 
in these patients. Additionally, it requires an explanation for 
the paradoxical persistence of a strong,  sustained  CTL re- 
sponse to the prototype epitope in the absence of detectable 
prototype virus. The paradox can be resolved if one postu- 
lates either recurrent stimulation by prototype peptide peri- 
odically  presented  to  CTL  recognition  from  a  currently 
undefined  reservoir  of prototype virus  or very long-term 
memory of a previous encounter with prototype virus (44--48). 
Consistent  with  the  first  possibility,  it  has  recently been 
demonstrated (49) that intravascular  HBV-specific, class I-re- 
stricted CTL that can recognize and destroy HBV antigen- 
positive hepatocytes in  transgenic  mice are simultaneously 
unable to recognize the same antigens expressed in other tissues 
(e.g., brain, kidney, testis, pancreas, gastrointestinal tract, etc.) 
in the same animals.  Further, it has been shown that the CTL 
ignore extrahepatic viral antigen because their access to an- 
tigen at these sites is precluded by microvascular anatomical 
barriers in these tissues that  do not exist in the sinusoidal 
structure of the liver. Based on these observations, it has been 
suggested that similar processes may contribute to viral per- 
sistence during natural infections. In view of these findings, 
it is conceivable that  these patients  may have been infected 
by a prototype virus that was eliminated from the liver (but 
not from these putative inaccessible extrahepatic sites) by the 
CTL response to  a single prototype epitope which  subse- 
quently led to negative selection of the variant genome that 
eventually dominated the intrahepatic virus population. Ac- 
cording to this scenario,  the HBV prototype would persist 
in the extrahepatic tissues despite a vigorous prototype-specific 
CTL response in the periphery, and prototype virions released 
from such protected sites could infect liver cells where they 
can maintain the prototype-specific CTL response as well as 
the associated chronic liver disease. 
Although we favor the foregoing scenario to explain the 
results of this study, it is important to remember that 100% 
of the viral genomes in these two patients contained substi- 
tutions at nucleotides 1896 and 1899 that introduce a stop 
codon in the precore region.  It is not likely that this prop- 
erty  could  have  led  to  immune  selection  of the  HBc18- 
27-variant viruses described in this report. However, if this 
or other associated mutations were eventually proven to confer 
a growth advantage to the variant virus, then selection could 
be explained on this basis, rather than by the pressure exerted 
by the CTL response. 
In conclusion, we believe that our results are most com- 
patible with the concept that variant viruses carrying substi- 
tutions  within  an  immunodominant  CTL  epitope  were 
selected by CTL pressure in these two patients because the 
anti-viral CTL response was narrowly focused on the proto- 
type epitope and because the variant epitopes did not induce 
a new population of CTL specific for themselves. It is im- 
portant to emphasize that while the results of our study may 
serve to demonstrate  that  such host-virus  interactions  can 
and do occur during naturally acquired HBV infection in man, 
we do not suggest that  this process is responsible for viral 
persistence in most patients with chronic HBV infection. Even 
if negative selection of CTL escape mutants eventually proves 
to be common during chronic HBV infection, their occur- 
rence is likely to accompany and aggravate,  not cause,  viral 
persistence which is likely due primarily to the development 
of a weak class I and II-restricted cellular immune response 
to the known viral antigens  (26,  30,  50). 
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